Searchable abstracts of presentations at key conferences in endocrinology

ea0030p65 | (1) | BSPED2012

Thyroid Hormone resistance: a case report

Ayuk Loveline , Kumbattae Umadevi

Thyroid hormone resistance is an inherited disorder with an incidence of about 1 in 50 000 live births. It is characterised by reduced response to the hormone at tissue level. Though many cases have been reported and there is growing awareness of the rare condition, there are reports of many patients being wrongly diagnosed as Graves disease and therefore undergoing various inappropriate treatments. We report the case of a 7-year-old boy who was referred to our service with ab...

ea0033p12 | (1) | BSPED2013

Brown tumours caused by severe vitamin D deficiency: a report of two cases

Ayuk Loveline , Hogler Wolfgang , Shaw Nick

Brown tumours are benign osteolytic lesions of bone caused by high levels of serum parathyroid hormone (PTH). They are now rarely seen as a feature of primary hyperparathyroidism. We report two cases of brown tumour in adolescent girls caused by secondary hyperparathyroidism due to severe vitamin D and dietary calcium deficiency.Case 1: 14.5-year-old South Asian girl referred with a 1 year history of right hip pain. She had presented to the orthopaedic t...

ea0030p27 | (1) | BSPED2012

Cerebral oedema in toddlers; risks and challenges: a case series

Sundaram Manu , Ayuk Loveline , Parakkal Raffeeq

Prevention, diagnosing, and adequate management of cerebral oedema in diabetic ketoacidosis are of vital importance. This can be very challenging in infants and toddlers as symptoms can be very subtle or difficult to interpret. Young age, new diagnosis of diabetes, and severe acidosis at presentation has been reported as risk factors for the development of cerebral oedema. We report our experience in managing one infant and two toddlers newly diagnosed diabetics who were refer...

ea0033p70 | (1) | BSPED2013

Growth hormone device change-over; is it beneficial?

Ayuk Loveline , Casey Angela , Prior Julia , Kirk Jeremy

Recombinant growth hormone (GH) administration uses several different injection devices. Despite offering free patient choice at GH therapy start, ~20% of our patients subsequently change GH device.Objective: To investigate reasons for GH device change, and evaluate the effect on adherence, height velocity standard deviation (HVSDS), and insulin-like growth factor-1 (IGF1).Method: Retrospective study of extracted growth data and la...